California Startup, BiologyWorks, Born During the COVID-19 Pandemic Improves Molecular Testing Today and Tomorrow
With support from the Bill and Melinda Gates Foundation and Alfred Mann Foundation
LOS ANGELES--(BUSINESS WIRE)-- BiologyWorks™, a medical test developer with a mission to deliver fast and accurate molecular testing, launches its innovative and affordable BiologyWorks k(now)™ test. The small handheld and affordable device delivers highly accurate answers about any infection or disease with a recognizable gene sequence, including COVID-19. BiologyWorks’ technologies are protected by multiple patents and offer certainty of results on par with PCR laboratory tests, considered the highest accuracy available today. BiologyWorks’ novel approach originated with the Alfred Mann Foundation and is supported by a generous grant from the Bill & Melinda Gates Foundation.
“We began our work in late 2019 to focus on developing a molecular test to help identify common respiratory infections, but when the COVID-19 global pandemic arrived, we pivoted to create an accurate, fast, portable, and affordable diagnostic test for SARS-CoV-2,” said Peter Marx, a founder of BiologyWorks. “We also built a digital platform to enable telemedicine and certificates. Our approach is usable for any number of different genetic biomarkers.”
Using technologies only recently available, BiologyWorks was able to develop a molecular test in less than a year that is accurate, fast, affordable, reusable and digital. Genetic sequences are found everywhere, which means BiologyWorks k(now) is useful for recognizing millions of organisms, infections, and biological processes, including Influenza A/B, Hepatitis B, Streptococcus, STDs, pneumonia and even, potentially, various cancers.
“Molecular testing has always been important to identify the things we cannot see,” noted Marx, “It goes almost without saying today that we need and will continue to need accurate and affordable tests.”
The BiologyWorks k(now) test has received a CE Mark and is available for sale for point of care in Europe and many parts of the world.
The BiologyWorks k(now) test is not authorized by the US Food and Drug Administration and, therefore, is not available for sale in the US.
BiologyWorks is a team of engineers, tech experts, scientists, businesspeople, and creatives focused on democratizing molecular tests.
BiologyWorks is the creator of BiologyWorks k(now), usable for quickly identifying COVID-19 infections with an accuracy akin to PCR. The BiologyWorks k(now) test is an affordable small, handheld device and sample kit using a nasal swab. The patented molecular testing technologies are effective in a multitude of use cases ranging from infections and diseases to education and sustainability. For more information, please visit: www.biologyworks.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005964/en/
View this news release online at: